LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Choi, Kati"
  2. AU="Wiese, Lothar"
  3. AU=Rackova Sylva AU=Rackova Sylva
  4. AU="Akala, Isiaka Olusola"
  5. AU="Nicolás Gonzalo Núñez"
  6. AU="Hernández Solis, Alejandro"
  7. AU="Jadad, Alejandro R"
  8. AU="Lastres, Palma Rico" AU="Lastres, Palma Rico"
  9. AU="Manes, K"
  10. AU="Baugh, Matthew"
  11. AU="Qu, C"
  12. AU="Flett, Heather"
  13. AU="Shueh Lin Lim"
  14. AU="Schröder, Johann"
  15. AU=Butler Taylor
  16. AU="Yang, Fan"
  17. AU="Giacomo Frati"
  18. AU=Kokhaei P
  19. AU="Charikleia Triantopoulou"
  20. AU="Salil Bhargava"
  21. AU="Jong-Eun Lee"
  22. AU="Vargas C, Laura"

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

  1. Artikel ; Online: Endoscopic patterns of the blebs in blue rubber bleb nevus syndrome.

    Jamali, Taher / Choi, Kati / Tasleem, Syed / Mansour, Nabil

    Gastrointestinal endoscopy

    2021  Band 93, Heft 5, Seite(n) 1181–1182

    Mesh-Begriff(e) Humans ; Gastrointestinal Neoplasms/surgery ; Nevus, Blue ; Skin Neoplasms
    Sprache Englisch
    Erscheinungsdatum 2021-01-06
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 391583-9
    ISSN 1097-6779 ; 0016-5107
    ISSN (online) 1097-6779
    ISSN 0016-5107
    DOI 10.1016/j.gie.2020.12.041
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 283: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 519: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Gastric Coccidioidomycosis Presenting As Gastric Outlet Obstruction.

    Jamali, Taher / Choi, Kati / Tasleem, Syed / Zarrin-Khameh, Neda / Sealock, Robert J

    The Korean journal of internal medicine

    2021  Band 37, Heft 1, Seite(n) 241–242

    Mesh-Begriff(e) Coccidioidomycosis/complications ; Coccidioidomycosis/diagnosis ; Coccidioidomycosis/drug therapy ; Gastric Outlet Obstruction/diagnostic imaging ; Gastric Outlet Obstruction/etiology ; Gastric Outlet Obstruction/surgery ; Humans
    Sprache Englisch
    Erscheinungsdatum 2021-03-17
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article
    ZDB-ID 639023-7
    ISSN 2005-6648 ; 1226-3303
    ISSN (online) 2005-6648
    ISSN 1226-3303
    DOI 10.3904/kjim.2020.688
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 3028: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Regarding: Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35(5):749-759. doi:10.1111/jgh.15053

    Gomez Cifuentes, Juan D / Sparkman, Jordan / Choi, Kati / Sealock, Robert J

    J. gastroenterol. hepatol

    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #32503087
    Datenquelle COVID19

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel: A simultaneous presentation of drug-induced lupus with drug-induced ANCA vasculitis secondary to hydralazine use in a patient with sarcoidosis.

    Espinosa, Maria Catalina / Ding, Belicia / Choi, Kati / Cohen, Daniel N / Marcelli, Marco / Ifoeze, Onome Whiteru

    Proceedings (Baylor University. Medical Center)

    2019  Band 32, Heft 2, Seite(n) 231–234

    Abstract: Frequently used in the management of hypertension and heart failure, hydralazine is associated with the development of adverse rheumatologic side effects. The authors highlight a unique case of drug-induced lupus and drug-induced anti-neutrophil ... ...

    Abstract Frequently used in the management of hypertension and heart failure, hydralazine is associated with the development of adverse rheumatologic side effects. The authors highlight a unique case of drug-induced lupus and drug-induced anti-neutrophil cytoplasmic antibody (ANCA) vasculitis from hydralazine use in a 50-year-old man with sarcoidosis and hypertension.
    Sprache Englisch
    Erscheinungsdatum 2019-03-27
    Erscheinungsland United States
    Dokumenttyp Case Reports
    ZDB-ID 2703932-8
    ISSN 1525-3252 ; 0899-8280
    ISSN (online) 1525-3252
    ISSN 0899-8280
    DOI 10.1080/08998280.2019.1570422
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6987: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

    Zou, Winnie Y / Choi, Kati / Kramer, Jennifer R / Yu, Xian / Cao, Yumei / El-Serag, Hashem B / Kanwal, Fasiha

    Digestive diseases and sciences

    2019  Band 64, Heft 11, Seite(n) 3328–3336

    Abstract: Background: With advent of direct-acting antiviral agents (DAA), hepatitis C virus (HCV) treatment is dramatically increasing. Although few studies reported rates of hepatocellular carcinoma (HCC) recurrence following DAA treatment, there have been no ... ...

    Abstract Background: With advent of direct-acting antiviral agents (DAA), hepatitis C virus (HCV) treatment is dramatically increasing. Although few studies reported rates of hepatocellular carcinoma (HCC) recurrence following DAA treatment, there have been no studies that followed sufficient number of DAA-treated patients after successful HCC treatment to examine HCC recurrence.
    Methods: We conducted a cohort study of HCV+ patients who had successfully treated HCC before initiating DAAs. We conducted medical record reviews to confirm HCC diagnosis, treatment, and remission prior to DAA initiation, and subsequent HCC recurrence. We calculated HCC recurrence rate and examined the recurrent tumor characteristics. We used Cox proportional hazard model to identify factors associated with HCC recurrence.
    Results: We identified 264 HCV+ patients who received DAAs after an average of 30.9 (20.6) months following HCC treatment. HCC recurred in 26.1% patients during 23.3 (9.8) months follow-up, at a rate of 0.38 [0.30, 0.48] per 1000 person-month. Most (82.3%) recurrent HCC were early stage. Receiving non-curative treatment for HCC was associated with a higher risk of recurrence than curative treatment (HR
    Conclusions: We conclude that most HCV+ patients with HCC benefit from DAA treatment; however, timing of DAA initiation after HCC treatment should be carefully considered.
    Mesh-Begriff(e) Aged ; Antiviral Agents/administration & dosage ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/epidemiology ; Cohort Studies ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/epidemiology ; Humans ; Liver Neoplasms/diagnosis ; Liver Neoplasms/drug therapy ; Liver Neoplasms/epidemiology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/epidemiology ; Risk Factors ; Treatment Outcome
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2019-04-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-019-05641-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui V Zs.35: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?

    Choi, Kati / Abu-Sbeih, Hamzah / Samdani, Rashmi / Nogueras Gonzalez, Graciela / Raju, Gottumukkala Subba / Richards, David M / Gao, Jianjun / Subudhi, Sumit / Stroehlein, John / Wang, Yinghong

    Inflammatory bowel diseases

    2018  Band 25, Heft 2, Seite(n) 385–393

    Abstract: Background: Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)-induced colitis. The main objective of this study was to characterize ICPI-induced MC by exploring the differences in risk factors, ... ...

    Abstract Background: Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)-induced colitis. The main objective of this study was to characterize ICPI-induced MC by exploring the differences in risk factors, colitis treatments, endoscopic features, and clinical outcomes between cancer and noncancer patients with MC with and without exposure to ICPIs.
    Methods: A retrospective chart review was conducted among patients diagnosed with MC from our institutional pathology database from January 2012 to January 2018. Patients were categorized into MC in cancer patients with or without ICPI exposure and in noncancer patients. Risk factors (use of tobacco and certain medications), colitis treatments (antidiarrheals and immunosuppressants), endoscopic features (with or without mucosal abnormality), and clinical outcomes (diarrhea recurrence, hospitalization, mortality) were collected and compared among the 3 groups.
    Results: Of the 65 eligible patients with MC, 15 cancer patients had exposure to ICPI, 39 cancer patients had no exposure to ICPI, and 11 had no cancer diagnosis. Among the risk factors, proton pump inhibitor was more frequently used in the ICPI-induced MC cohort (P = 0.040). Furthermore, in this population, mucosal abnormality was the most common endoscopic feature compared with normal findings in the non-ICPI-induced MC groups (P = 0.106). Patients with ICPI-induced MC required more treatments with oral and intravenous steroids and nonsteroidal immunosuppressive agents (all P < 0.001) and had a higher rate of hospitalization (P < 0.001).
    Conclusion: This study suggests that despite some similarities between MC with and without exposure to ICPIs, ICPI-induced MC has a more aggressive disease course that requires more potent immunosuppressive treatment regimens and greater need for hospitalization. 10.1093/ibd/izy240_video1izy240.video15828223597001.
    Mesh-Begriff(e) Antineoplastic Agents, Immunological/adverse effects ; Case-Control Studies ; Cell Cycle Checkpoints/drug effects ; Colitis/chemically induced ; Colitis/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasms/complications ; Neoplasms/drug therapy ; Prognosis ; Proton Pump Inhibitors/adverse effects ; Retrospective Studies
    Chemische Substanzen Antineoplastic Agents, Immunological ; Proton Pump Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2018-08-30
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izy240
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4530: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients.

    Abu-Sbeih, Hamzah / Choi, Kati / Tran, Cynthia N / Wang, Xuemei / Lum, Phillip / Shuttlesworth, Gladis / Stroehlein, John R / Okhuysen, Pablo C / Wang, Yinghong

    European journal of gastroenterology & hepatology

    2018  Band 31, Heft 1, Seite(n) 128–134

    Abstract: Background: Cancer patients are susceptible to recurrent Clostridium difficile infection (CDI) that is increasing globally, necessitating new approaches to prevent fatal consequences. We examined the clinical characteristics of cancer patients with ... ...

    Abstract Background: Cancer patients are susceptible to recurrent Clostridium difficile infection (CDI) that is increasing globally, necessitating new approaches to prevent fatal consequences. We examined the clinical characteristics of cancer patients with recurrent CDI (RCDI).
    Patients and methods: A retrospective review of cancer patients with C. difficile-positive test between January 2015 and May 2017 was carried out. CDI was defined as diarrhea and toxigenic C. difficile detection in the stool by nucleic acid amplification test and enzyme immunoassay. Patients having two CDI episodes were categorized as single recurrent CDI (SRCDI), and those having three or more CDI episodes were categorized as multiple recurrent CDI (MRCDI). Treatment failure was defined as the requirement of antimicrobial alteration or repetition.
    Results: We included 170 patients having 270 CDI episodes; 85 patients had non-RCDI, and 85 had RCDI; 14 of them had MRCDI. Previous hospitalization and immunosuppressant use were more frequent in MRCDI group than in SRCDI group (P=0.009 and 0.002, respectively). Physicians treated more SRCDI episodes than MRCDI episodes with metronidazole alone (P=0.017), whereas, more MRCDI episodes needed combination antimicrobials (P=0.072). The mean duration of CDI treatment was longer in the MRCDI group than in the SRCDI group (P=0.030). MRCDI was associated with treatment failure more than SRCDI (P=0.021). The risk for a recurrent episode of CDI was increased in patients who had the following features of the first CDI episode: previous use of antibiotic, NSAID, immunosuppressant, chemotherapy, comorbidities, CDI treatment failure, and severe CDI (P<0.05).
    Conclusion: Risk factors for RCDI in cancer patients are similar to those without cancer, with the exception of chemotherapy that is only given to cancer patients. Long CDI treatment and CDI treatment failure are associated with MRCDI.
    Mesh-Begriff(e) Adult ; Aged ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Clostridium Infections/diagnosis ; Clostridium Infections/drug therapy ; Clostridium Infections/epidemiology ; Clostridium Infections/microbiology ; Comorbidity ; Databases, Factual ; Drug Administration Schedule ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/epidemiology ; Recurrence ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Texas/epidemiology ; Time Factors ; Treatment Failure
    Chemische Substanzen Anti-Bacterial Agents ; Anti-Inflammatory Agents, Non-Steroidal ; Antineoplastic Agents ; Immunosuppressive Agents
    Sprache Englisch
    Erscheinungsdatum 2018-10-19
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1034239-4
    ISSN 1473-5687 ; 0954-691X
    ISSN (online) 1473-5687
    ISSN 0954-691X
    DOI 10.1097/MEG.0000000000001288
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2932: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

    Wang, Yinghong / Wiesnoski, Diana H / Helmink, Beth A / Gopalakrishnan, Vancheswaran / Choi, Kati / DuPont, Hebert L / Jiang, Zhi-Dong / Abu-Sbeih, Hamzah / Sanchez, Christopher A / Chang, Chia-Chi / Parra, Edwin R / Francisco-Cruz, Alejandro / Raju, Gottumukkala S / Stroehlein, John R / Campbell, Matthew T / Gao, Jianjun / Subudhi, Sumit K / Maru, Dipen M / Blando, Jorge M /
    Lazar, Alexander J / Allison, James P / Sharma, Padmanee / Tetzlaff, Michael T / Wargo, Jennifer A / Jenq, Robert R

    Nature medicine

    2018  Band 25, Heft 1, Seite(n) 188

    Abstract: In the version of this article originally published, an author was missing from the author list. Alexander J. Lazar should have been included between Jorge M. Blando and James P. Allison. The author has been added to the list, and the author ... ...

    Abstract In the version of this article originally published, an author was missing from the author list. Alexander J. Lazar should have been included between Jorge M. Blando and James P. Allison. The author has been added to the list, and the author contributions section has been updated to include Alexander J. Lazar's contribution to the study. The error has been corrected in the print, PDF and HTML versions of the manuscript.
    Sprache Englisch
    Erscheinungsdatum 2018-11-27
    Erscheinungsland United States
    Dokumenttyp Published Erratum
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-018-0305-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4212: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

    Wang, Yinghong / Wiesnoski, Diana H / Helmink, Beth A / Gopalakrishnan, Vancheswaran / Choi, Kati / DuPont, Hebert L / Jiang, Zhi-Dong / Abu-Sbeih, Hamzah / Sanchez, Christopher A / Chang, Chia-Chi / Parra, Edwin R / Francisco-Cruz, Alejandro / Raju, Gottumukkala S / Stroehlein, John R / Campbell, Matthew T / Gao, Jianjun / Subudhi, Sumit K / Maru, Dipen M / Blando, Jorge M /
    Lazar, Alexander J / Allison, James P / Sharma, Padmanee / Tetzlaff, Michael T / Wargo, Jennifer A / Jenq, Robert R

    Nature medicine

    2018  Band 24, Heft 12, Seite(n) 1804–1808

    Abstract: We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells ...

    Abstract We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis.
    Mesh-Begriff(e) Aged ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; CTLA-4 Antigen/therapeutic use ; Colitis/chemically induced ; Colitis/immunology ; Colitis/microbiology ; Colitis/therapy ; Fecal Microbiota Transplantation/methods ; Female ; Gastrointestinal Microbiome/drug effects ; Gastrointestinal Microbiome/immunology ; Humans ; Immune System/drug effects ; Immune System/microbiology ; Intestinal Mucosa/immunology ; Intestinal Mucosa/microbiology ; Intestinal Mucosa/pathology ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/therapeutic use ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/microbiology
    Chemische Substanzen CTLA-4 Antigen ; Ipilimumab ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
    Sprache Englisch
    Erscheinungsdatum 2018-11-12
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-018-0238-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4212: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang